GO
Loading...

Pharmaceuticals

More

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Teva considering bid for Mylan: DJ   Friday, 17 Apr 2015 | 2:25 PM ET
    Teva considering bid for Mylan: DJ

    CNBC's Meg Tirrell provides insight to a report on Teva Pharmaceutical Industries Ltd. exploring a takeover offer from Mylan.

  • Glaxo recalls flu vaccine due to potency problem Friday, 17 Apr 2015 | 1:24 PM ET

    WASHINGTON— GlaxoSmithKline is recalling remaining doses of a popular four-in-one flu vaccine because of effectiveness problems. But Glaxo said in a letter it "cannot rule out potential suboptimal protection" in people who received the vaccine in early January or later. More than 99 percent of the vaccines were distributed in 2014, before the product began...

  • The generic, called Glatopa, is made by Sandoz, a unit of Swiss drug company Novartis AG, and U.S.-based Momenta Pharmaceuticals. The Food and Drug Administration approved the drug Thursday. But Teva Pharmaceutical Industries, which makes Copaxone, has said it expects generic versions of the drug to go on sale in the U.S. in September.

  • A promising treatment from Bristol-Myers Squibb may be fast-tracking toward another approved use after researchers stopped a study early because the drug did better than an older treatment in patients with an advanced form of lung cancer. Shares of the New York drugmaker jumped Friday morning after it said Opdivo fared better than the chemotherapy drug...

  • Exciting time for drug breakthroughs: Merck CEO   Thursday, 16 Apr 2015 | 2:12 PM ET
    Exciting time for drug breakthroughs: Merck CEO

    Ken Frazier, Merck Chairman & CEO, discusses challenges facing the healthcare industry and the launch of new medicines. We will see great drugs going forward, says Frazier.

  • Need to change the laws on corporate tax: Pfizer CEO

    Ian Read, Pfizer Chairman & CEO, discusses accomplishments and breakthroughs that have taken place in the past year in the pharmaceuticals sector and gives a read on taxes.

  • The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...

  • April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...

  • LONDON, April 16- Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to extend lives for prostate cancer sufferers. Ipsen stock was down 10 percent in early trade while Active Biotech, which originally developed the drug, slumped 60 percent.

  • LONDON, April 16- Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to extend lives for prostate cancer sufferers. As a result, the companies said they had decided to discontinue all studies of tasquinimod in prostate cancer, torpedoing sales...

  • MUMBAI, April 15- India may go to the World Trade Organisation if the European Union does not reconsider a decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • TOKYO, April 16- Japanese stocks slipped to more than a one-week low on Thursday morning as investors cut back on some recent outperformers including food companies and drugmakers, while Sharp Corp surged on restructuring hopes. Rising oil prices lifted oil and mining stocks, with Inpex Corp soaring 3.6 percent, Japan Petroleum Exploration gaining 2.1...

  • FDA approves new type of heart failure drug from Amgen Wednesday, 15 Apr 2015 | 4:53 PM ET

    TRENTON, N.J.— Patients with chronic heart failure, a disabling, deadly disease that worsens as the heart gradually pumps less efficiently, are getting a much-needed new option with U.S. approval Wednesday of a novel drug from Amgen Inc.. Meanwhile, the Food and Drug Administration is reviewing another heart failure pill, from Novartis AG, and could approve it this...

  • MUMBAI, April 15- India may go to the World Trade Organization if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • *Intel capital expenditure cut hits chip-related shares. *Obayashi gains after raising earnings outlook. TOKYO, April 15- Japan's Nikkei share average was flat on Wednesday as investors took profits on recent gainers such as drugmakers, but expectations that companies will report strong profits supported sentiment.

  • UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln Tuesday, 14 Apr 2015 | 6:23 PM ET

    Aduro, which counts Johnson& Johnson and Swiss drugmaker Novartis AG among its investors, is selling all the 7 million shares in the offering. To gain access to Aduro's cancer immunotherapy technology, Novartis last month entered into a tie-up worth about $750 million with the company. Novartis Institutes for BioMedical Research Inc, an affiliate of Novartis,...

  • IBM takes medical data to the cloud   Tuesday, 14 Apr 2015 | 10:39 AM ET
    IBM takes medical data to the cloud

    Mike Rhodin, IBM Watson, weighs in on the future of IBM's Watson Health Cloud

  • J&J earnings beat despite THIS factor Tuesday, 14 Apr 2015 | 9:25 AM ET
    Johnson & Johnson gauze pads

    Johnson & Johnson reports quarterly earnings that beat expectations despite a 7.2 percent drag on the strong dollar.

  • Johnson & Johnson beats Street 1Q forecasts Tuesday, 14 Apr 2015 | 7:54 AM ET

    Johnson& Johnson's first-quarter profit uncharacteristically fell 8.6 percent, hurt by sharply unfavorable exchange rates, a major divestiture and competition to its new hepatitis C drug. However, Johnson& Johnson reduced its full-year profit forecast, saying it now expects earnings of $6.04 to $6.19 per share, down from $6.12 to $6.27.